Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2003-07-16
2010-06-22
Eyler, Yvonne L (Department: 1619)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S934000, C514S274000
Reexamination Certificate
active
07741372
ABSTRACT:
There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.
REFERENCES:
patent: 5574040 (1996-11-01), Bukrinsky et al.
patent: 5599984 (1997-02-01), Bianchi et al.
patent: 5616578 (1997-04-01), Otto
patent: 5750573 (1998-05-01), Bianchi et al.
patent: 5753446 (1998-05-01), Johnson
patent: 5753684 (1998-05-01), Bianchi et al.
patent: 5849794 (1998-12-01), Bianchi et al.
patent: 5854289 (1998-12-01), Bianchi et al.
patent: 5859062 (1999-01-01), Bianchi et al.
patent: 6008255 (1999-12-01), Bianchi et al.
patent: 6022900 (2000-02-01), Bianchi et al.
patent: 6143728 (2000-11-01), Tracey et al.
patent: 6180676 (2001-01-01), Bianchi et al.
patent: 6218136 (2001-04-01), Kumar et al.
patent: 6248787 (2001-06-01), Bianchi et al.
patent: 6673777 (2004-01-01), Tracey et al.
Bianchi et al. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Molecular Medicine (Baltimore, MD, United States) (1995), 1(3), 254-66.
Levine et al. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial.J Clin Oncol. Mar. 1997;15(3):1094-103.
Kumar et al. Activation of the HIV-1 Long Terminal Repeat by Cytokines and Environmental Stress Requires an Active CSBP/p38 MAP Kinase. The Journal of Biological Chemistry (271), No. 48. pp. 30864-30869. Nov. 29, 1996.
Bianchi et al., Suppression of Proinflammatory Cytokines in Monocytes by a Tetravalent Guanylhydrazone, J. Exp. Med. vol. 183 Mar. 1996 pp. 927-936.
Barré-Sinoussi, F., et al., “Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)”, Science, vol. 220, pp. 868-870 (1983).
Gallo, R.C., et al., “Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS”, vol. 224, pp. 500-503 (1984).
Teich, N., et al., “RNA Tumor Viruses”, Weiss, et al., eds., Cold Spring Harbor Laboratory, pp. 949-956 (1984).
Mitsuya, H., et al., “Molecular Targets for AIDS Therapy”, Science, vol. 249, pp. 1533-1544 (1990). (cited as “1991” in specification).
Larder, B.A., et al., “HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy”, Science, vol. 243, pp. 1731-1734 (1989). (cited in specification as “Lander et al.”).
Erickson, J., et al., “Design, Activity, and 2.8 Å Crystal Structure of a C2Symmetric Inhibitor Complexed to HIV-1 Protease”, Science, vol. 249, pp. 527-533 (1990).
Marshall, C.J., et al., “Specificity of Receptor Tyrosine Kinase Signaling: Transient Versus Sustained Extracellular Signal-Regulated Kinase Activation”, Cell, vol. 80, pp. 179-185 (1995).
Galcheva-Gargova, Z., et al., “An Osmosensing Signal Transduction Pathway in Mammalian Cells”, Science, vol. 265, pp. 806-808 (1994).
Kyriakis, J.M., et al., “The Stress-Activated Protein Kinase Subfamily of c-Jun Kinases”, Nature, vol. 369, pp. 156-160 (1994).
Raingeaud, J., et al., “Pro-Inflammatory Cytokines and Environmental Stress Cause p38 Mitogen-Activated Protein Kinase Activation by Dual Phosphorylation on Tyrosine and Threonine”, The Journal of Biological Chemistry, vol. 270, No. 13, pp. 7420-7426 (1995).
Han, J., et al., “A MAP Kinase Targeted by Endotoxin and Hypersmolarity in Mammalian Cells”, Science, vol. 265, pp. 808-811 (1994).
Brewster, J.L., et al., “An Osmosensing Signal Transduction Pathway in Yeast”, Science, vol. 259, pp. 1760-1763 (1993).
Rouse, J., et al., “A Novel Kinase Cascade Triggered by Stress and Heat Shock that Stimulates MAPKAP Kinase-2 and Phosphorylation of the Small Heat Shock Proteins”, Cell, vol. 78, pp. 1027-1037 (1994).
Lee, J.C., et al., “A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis”, Nature, vol. 372, pp. 739-746 (1994).
Sen, J., et al., “Intrathymic Signals in Thymocytes are Mediated by p38 Mitogen-Activated Protein Kinase”, The Journal of Immunology, pp. 4535-4538 (1996).
Batchvarova, N., et al., “Inhibition of Adipogenesis by the Stress-Induced Protein CHOP (Gadd153)”, The EMBO Journal, vol. 14, No. 19, pp. 4654-4661 (1995).
Freshney, N.W., et al., “A Novel Protein Kinase Cascade that Results in the Phosphorylation of Hsp27”, Cell, vol. 78, pp. 1039-1049 (1994).
Zervos, A.S., et al., “Mxi2, a Mitogen-Activated Protein Kinase that Recognizes and Phosphorylates Max Protein”, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 10531-10534 (1995).
Geng, Y., et al., “Protein Tyrosine Kinase Activation is Required for Lipopolysaccharide Induction of Cytokines in Human Blood Monocytes”, The Journal of Immunology, vol. 151, No. 12, pp. 6692-6700 (1993).
Stein et al., Science vol. 261, pp. 1004-1012, Aug. 20, 1993.
McLaughlin, M.M., et al., “Identification of Mitogen-Activated Protein (MAP) Kinase-Activated Protein Kinase-3, a Novel Substrate of CSBP p38 MAP Kinase”, The Journal of Biological Chemistry, vol. 271, No. 14, pp. 8488-8492 (1996).
Beyaert, R., et al., “The p38/RK Mitogen-Activated Protein Kinase Pathway Regulates Interleukin-6 Synthesis in Response to Tumour Necrosis Factor”, The EMBO Journal, vol. 15, No. 8, pp. 1914-1923 (1996).
Shapiro, L., et al., “Specific Inhibition of P38 Mitogen Activated Protein (MAP) Kinase Inhibits in vitro HIV Replication in U1 Cells Induced by Interleukin (IL)-1, Tumor Necrosis Factor (TNF) or Phorbol Esters (PMA)”, Eur. Cytokine Network, vol. 7, No. 3, Article No. 375 (1996).
Kumar, S., et al., “Activation of the HIV LTR by UV, Cytokines and High Osmolarity Requires CSBP/p38 Activation”, Eur. Cytokine Network, vol. 7, No. 3, Article No. 380 (1996).
Han, J., et al., “Molecular Cloning of Human p38 MAP Kinase”, Biochemica et Biophysica Act, vol. 1265, pp. 224-227 (1995).
Schmidtmayerova, H., et al., “Human Immunodeficiency Virus Type 1 Infection Alters Chemokine β Peptide Expression in Human Monocytes: Implications for Recruitment of Leukocytes into Brain and Lymph Nodes”, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 700-704 (1996).
Ho, D.D., et al., “Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection”, Nature, vol. 373, pp. 123-126 (1995).
Bukrinsky Michael
Cohen Pamela
Schmidtmayerova Helena
Tracey Kevin J.
Cytokine PharmaSciences, Inc.
Eyler Yvonne L
Jagoe Donna
Law Office of John K. Pike, PLLC
Pike John K.
LandOfFree
Guanylhydrazones useful for treating diseases associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guanylhydrazones useful for treating diseases associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guanylhydrazones useful for treating diseases associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244397